[
  {
    "ts": null,
    "headline": "Why Merck (MRK) is a Top Growth Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=ba4fccfdbe53e7e7d6075491034eabbaf4af72951cc90110fb873b4730ab03c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767883503,
      "headline": "Why Merck (MRK) is a Top Growth Stock for the Long-Term",
      "id": 138038415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=ba4fccfdbe53e7e7d6075491034eabbaf4af72951cc90110fb873b4730ab03c9"
    }
  },
  {
    "ts": null,
    "headline": "Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe",
    "summary": "Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.",
    "url": "https://finnhub.io/api/news?id=18fee4ac493307678d6e413a3de5a44a43dcb2809d2960b53f66d8b5ef0b79ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881018,
      "headline": "Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe",
      "id": 138036624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.",
      "url": "https://finnhub.io/api/news?id=18fee4ac493307678d6e413a3de5a44a43dcb2809d2960b53f66d8b5ef0b79ad"
    }
  },
  {
    "ts": null,
    "headline": "Cramer’s Stop Trading: Merck",
    "summary": "CNBC’s Jim Cramer explains why he is keeping an eye on shares of Merck.",
    "url": "https://finnhub.io/api/news?id=66c2a465884425f8d7ab92031b05774da4d927e2d6f503509b85aecde4d2adaf",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767867569,
      "headline": "Cramer’s Stop Trading: Merck",
      "id": 138037879,
      "image": "https://image.cnbcfm.com/api/v1/image/108249946-17678844971767884494-43394051000-1080pnbcnews.jpg?v=1767884496&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "CNBC’s Jim Cramer explains why he is keeping an eye on shares of Merck.",
      "url": "https://finnhub.io/api/news?id=66c2a465884425f8d7ab92031b05774da4d927e2d6f503509b85aecde4d2adaf"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Fundamentals Amplified By A Momentum Breakout",
    "summary": "Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=5fce5ae918fe5d01263af90c63596dab70b665c4953cbc0ba6073504f8f2dc1f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767859232,
      "headline": "Merck: Fundamentals Amplified By A Momentum Breakout",
      "id": 138035419,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186697175/image_2186697175.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=5fce5ae918fe5d01263af90c63596dab70b665c4953cbc0ba6073504f8f2dc1f"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?",
    "summary": "The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.",
    "url": "https://finnhub.io/api/news?id=a68c432a18f895735a6ecdd21dd81eee41702b5c4d867a15525d58b4a439f38c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767859200,
      "headline": "Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?",
      "id": 138036695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.",
      "url": "https://finnhub.io/api/news?id=a68c432a18f895735a6ecdd21dd81eee41702b5c4d867a15525d58b4a439f38c"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
    "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
    "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767850200,
      "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
      "id": 138034430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
      "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19"
    }
  }
]